GlaxoSmithKline Enterprise Value:
165.77B for May 17, 2013GlaxoSmithKline Historical Enterprise Value Data
Pro Data ExportThere is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| May 17, 2013 | 165.77B |
| May 16, 2013 | 165.45B |
| May 15, 2013 | 166.40B |
| May 14, 2013 | 164.40B |
| May 13, 2013 | 164.26B |
| May 10, 2013 | 164.13B |
| May 9, 2013 | 161.65B |
| May 8, 2013 | 161.92B |
| May 7, 2013 | 163.10B |
| May 6, 2013 | 162.51B |
| May 3, 2013 | 163.10B |
| May 2, 2013 | 163.62B |
| May 1, 2013 | 163.80B |
| April 30, 2013 | 164.18B |
| April 29, 2013 | 166.29B |
| April 26, 2013 | 165.59B |
| April 25, 2013 | 164.61B |
| April 24, 2013 | 163.40B |
| April 23, 2013 | 162.78B |
| April 22, 2013 | 161.51B |
| April 19, 2013 | 160.94B |
| April 18, 2013 | 160.81B |
| April 17, 2013 | 160.67B |
| April 16, 2013 | 158.08B |
| April 15, 2013 | 157.68B |
| April 12, 2013 | 155.63B |
| April 11, 2013 | 155.76B |
| April 10, 2013 | 153.68B |
| April 9, 2013 | 152.52B |
| April 8, 2013 | 151.85B |
| April 5, 2013 | 151.09B |
| April 4, 2013 | 151.61B |
| April 3, 2013 | 151.58B |
| April 2, 2013 | 151.58B |
| April 1, 2013 | 151.36B |
| March 28, 2013 | 150.73B |
| March 27, 2013 | 149.30B |
| March 26, 2013 | 148.28B |
| March 25, 2013 | 149.19B |
| March 22, 2013 | 149.46B |
| March 21, 2013 | 148.33B |
| March 20, 2013 | 148.01B |
| March 19, 2013 | 147.63B |
| March 18, 2013 | 145.90B |
| March 15, 2013 | 146.39B |
| March 14, 2013 | 146.17B |
| March 13, 2013 | 144.55B |
| March 12, 2013 | 144.63B |
| March 11, 2013 | 144.63B |
| March 8, 2013 | 144.44B |
About Enterprise Value
Click "Learn More" below to see how YCharts calculates Enterprise Value.
Enterprise Value (EV) is a valuation metric alternative to traditional market capitalization that reflects the market value of an entire business. Like market cap, EV is a measure of what the market believes a company is worth. Enterprise value captures the cost of an entire business, including debt and equity. It is a sum of claims of all preferred shareholders, debt holders, security holders, common equity holders, and minority shareholders - unlike market cap, which only captures the total value of common equity securities.
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Learn More
GSK Enterprise Value Benchmarks
| Companies | |
|---|---|
| Pfizer | 213.48B |
| Sanofi | 156.12B |
| AstraZeneca | 66.84B |
GSK Enterprise Value Rankings
| Overall |
99th percentile 34 of 8007 |
| Sector |
99th percentile 4 of 685 in Healthcare |
| Industry |
92nd percentile 4 of 54 in Drug Manufacturers - Major |
GSK Enterprise Value Range, Past 5 Years
| Minimum | 84.77B | Mar 9 2009 |
| Maximum | 166.40B | May 15 2013 |
| Average | 122.58B |
